Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
- Conditions
- Bacterial Infections
- Registration Number
- NCT03780140
- Lead Sponsor
- Shionogi
- Brief Summary
Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of cefiderocol in targeting iron-dependent Gram-negative bacteria?
How does cefiderocol compare to carbapenems in treating multidrug-resistant Gram-negative infections?
Which biomarkers are used to identify patients suitable for cefiderocol expanded access programs?
What are the most common adverse events associated with cefiderocol intravenous therapy and how are they managed?
Are there any combination therapies involving cefiderocol and other beta-lactam antibiotics for severe bacterial infections?